Annual CFF
-$9.17 B
-$1.83 B-24.88%
31 December 2023
Summary:
Novo Nordisk A/S annual cash flow from financing activities is currently -$9.17 billion, with the most recent change of -$1.83 billion (-24.88%) on 31 December 2023. During the last 3 years, it has fallen by -$4.23 billion (-85.60%). NVO annual CFF is now -2668.63% below its all-time high of $356.99 million, reached on 31 December 1991.NVO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$2.74 B
-$5.18 B-212.22%
30 September 2024
Summary:
Novo Nordisk A/S quarterly cash flow from financing activities is currently -$2.74 billion, with the most recent change of -$5.18 billion (-212.22%) on 30 September 2024. Over the past year, it has increased by +$151.01 million (+5.22%). NVO quarterly CFF is now -212.22% below its all-time high of $2.44 billion, reached on 30 June 2024.NVO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$5.56 B
+$151.01 M+2.64%
30 September 2024
Summary:
Novo Nordisk A/S TTM cash flow from financing activities is currently -$5.56 billion, with the most recent change of +$151.01 million (+2.64%) on 30 September 2024. Over the past year, it has increased by +$3.55 billion (+38.94%). NVO TTM CFF is now -2114.06% below its all-time high of -$251.34 million, reached on 31 March 2004.NVO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.9% | +5.2% | +38.9% |
| 3 y3 years | -85.6% | -52.7% | -18.5% |
| 5 y5 years | -67.7% | -87.6% | -6.1% |
NVO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -126.0% | at low | -212.2% | +28.7% | -37.2% | +44.6% |
| 5 y | 5 years | -126.0% | at low | -212.2% | +28.7% | -37.2% | +44.6% |
| alltime | all time | -2668.6% | at low | -212.2% | +28.7% | -2114.1% | +44.6% |
Novo Nordisk A/S Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.74 B(-212.2%) | -$5.56 B(-2.6%) |
| June 2024 | - | $2.44 B(-163.6%) | -$5.72 B(-43.1%) |
| Mar 2024 | - | -$3.84 B(+169.9%) | -$10.04 B(+9.5%) |
| Dec 2023 | -$9.17 B(+24.9%) | -$1.42 B(-50.8%) | -$9.17 B(+0.6%) |
| Sept 2023 | - | -$2.89 B(+53.8%) | -$9.11 B(+14.4%) |
| June 2023 | - | -$1.88 B(-36.8%) | -$7.96 B(+7.2%) |
| Mar 2023 | - | -$2.97 B(+117.3%) | -$7.43 B(+1.2%) |
| Dec 2022 | -$7.34 B(+81.0%) | -$1.37 B(-21.4%) | -$7.34 B(+39.4%) |
| Sept 2022 | - | -$1.74 B(+29.4%) | -$5.27 B(-1.0%) |
| June 2022 | - | -$1.35 B(-53.4%) | -$5.32 B(+15.8%) |
| Mar 2022 | - | -$2.89 B(-508.6%) | -$4.60 B(+13.3%) |
| Dec 2021 | -$4.06 B(-17.9%) | $706.40 M(-139.3%) | -$4.06 B(-13.6%) |
| Sept 2021 | - | -$1.80 B(+189.1%) | -$4.69 B(-1.8%) |
| June 2021 | - | -$621.02 M(-73.5%) | -$4.78 B(-9.7%) |
| Mar 2021 | - | -$2.35 B(-3534.5%) | -$5.29 B(+7.1%) |
| Dec 2020 | -$4.94 B(-7.1%) | $68.32 M(-103.6%) | -$4.94 B(-15.1%) |
| Sept 2020 | - | -$1.88 B(+65.6%) | -$5.82 B(+7.7%) |
| June 2020 | - | -$1.13 B(-43.1%) | -$5.40 B(+2.7%) |
| Mar 2020 | - | -$1.99 B(+146.4%) | -$5.26 B(-1.2%) |
| Dec 2019 | -$5.32 B(-2.7%) | -$809.38 M(-44.6%) | -$5.32 B(+1.5%) |
| Sept 2019 | - | -$1.46 B(+47.4%) | -$5.24 B(-2.6%) |
| June 2019 | - | -$991.30 M(-51.8%) | -$5.38 B(+3.6%) |
| Mar 2019 | - | -$2.06 B(+181.0%) | -$5.19 B(-5.0%) |
| Dec 2018 | -$5.47 B(+0.7%) | -$732.56 M(-54.3%) | -$5.47 B(+4.1%) |
| Sept 2018 | - | -$1.60 B(+99.7%) | -$5.26 B(-7.6%) |
| June 2018 | - | -$801.92 M(-65.6%) | -$5.69 B(-1.9%) |
| Mar 2018 | - | -$2.33 B(+348.9%) | -$5.80 B(+6.7%) |
| Dec 2017 | -$5.43 B(-6.0%) | -$519.59 M(-74.5%) | -$5.43 B(-0.8%) |
| Sept 2017 | - | -$2.04 B(+123.8%) | -$5.48 B(+7.9%) |
| June 2017 | - | -$910.12 M(-53.7%) | -$5.07 B(-2.5%) |
| Mar 2017 | - | -$1.97 B(+249.2%) | -$5.21 B(-9.9%) |
| Dec 2016 | -$5.78 B(+29.1%) | -$563.10 M(-65.6%) | -$5.78 B(-1.6%) |
| Sept 2016 | - | -$1.64 B(+56.8%) | -$5.87 B(+17.5%) |
| June 2016 | - | -$1.04 B(-58.9%) | -$5.00 B(+3.3%) |
| Mar 2016 | - | -$2.54 B(+286.0%) | -$4.84 B(+8.1%) |
| Dec 2015 | -$4.48 B(-5.4%) | -$657.78 M(-13.5%) | -$4.48 B(-1.0%) |
| Sept 2015 | - | -$760.74 M(-14.0%) | -$4.52 B(+3.9%) |
| June 2015 | - | -$884.11 M(-59.4%) | -$4.35 B(-3.0%) |
| Mar 2015 | - | -$2.18 B(+209.5%) | -$4.49 B(-5.1%) |
| Dec 2014 | -$4.73 B(+12.4%) | -$702.88 M(+18.8%) | -$4.73 B(+3.5%) |
| Sept 2014 | - | -$591.83 M(-41.9%) | -$4.57 B(+1.0%) |
| June 2014 | - | -$1.02 B(-57.9%) | -$4.53 B(-3.7%) |
| Mar 2014 | - | -$2.42 B(+344.1%) | -$4.71 B(+11.8%) |
| Dec 2013 | -$4.21 B(+21.0%) | -$544.69 M(-0.7%) | -$4.21 B(+4.0%) |
| Sept 2013 | - | -$548.45 M(-54.1%) | -$4.05 B(+7.9%) |
| June 2013 | - | -$1.19 B(-37.9%) | -$3.75 B(-0.4%) |
| Mar 2013 | - | -$1.92 B(+400.9%) | -$3.77 B(+8.4%) |
| Dec 2012 | -$3.48 B | -$383.65 M(+51.2%) | -$3.48 B(-3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | -$253.72 M(-79.0%) | -$3.61 B(-15.1%) |
| June 2012 | - | -$1.21 B(-25.7%) | -$4.25 B(+21.8%) |
| Mar 2012 | - | -$1.63 B(+217.6%) | -$3.49 B(+11.1%) |
| Dec 2011 | -$3.14 B(+33.4%) | -$513.03 M(-42.6%) | -$3.14 B(+6.5%) |
| Sept 2011 | - | -$894.01 M(+98.9%) | -$2.95 B(+5.4%) |
| June 2011 | - | -$449.57 M(-64.9%) | -$2.80 B(+7.3%) |
| Mar 2011 | - | -$1.28 B(+298.6%) | -$2.61 B(+10.7%) |
| Dec 2010 | -$2.35 B(+25.2%) | -$321.69 M(-56.6%) | -$2.35 B(+3.4%) |
| Sept 2010 | - | -$742.02 M(+185.7%) | -$2.28 B(+8.6%) |
| June 2010 | - | -$259.69 M(-74.8%) | -$2.10 B(-1.3%) |
| Mar 2010 | - | -$1.03 B(+321.7%) | -$2.12 B(+13.0%) |
| Dec 2009 | -$1.88 B(+29.2%) | -$244.26 M(-56.6%) | -$1.88 B(+1.7%) |
| Sept 2009 | - | -$562.24 M(+96.0%) | -$1.85 B(+12.7%) |
| June 2009 | - | -$286.92 M(-63.5%) | -$1.64 B(+4.9%) |
| Mar 2009 | - | -$786.49 M(+268.9%) | -$1.56 B(+7.5%) |
| Dec 2008 | -$1.46 B(+15.6%) | -$213.21 M(-39.8%) | -$1.46 B(-10.4%) |
| Sept 2008 | - | -$354.42 M(+68.8%) | -$1.62 B(-7.8%) |
| June 2008 | - | -$209.98 M(-69.0%) | -$1.76 B(+12.6%) |
| Mar 2008 | - | -$677.61 M(+77.2%) | -$1.57 B(+24.4%) |
| Dec 2007 | -$1.26 B(+57.0%) | -$382.37 M(-22.2%) | -$1.26 B(+48.0%) |
| Sept 2007 | - | -$491.74 M(+3599.5%) | -$850.45 M(+10.4%) |
| June 2007 | - | -$13.29 M(-96.4%) | -$770.16 M(-4.2%) |
| Mar 2007 | - | -$370.90 M(-1555.5%) | -$804.05 M(+0.3%) |
| Dec 2006 | -$801.30 M(+8.3%) | $25.48 M(-106.2%) | -$801.30 M(-9.6%) |
| Sept 2006 | - | -$411.45 M(+772.0%) | -$886.08 M(+44.7%) |
| June 2006 | - | -$47.18 M(-87.2%) | -$612.34 M(-22.4%) |
| Mar 2006 | - | -$368.15 M(+520.8%) | -$789.25 M(+6.6%) |
| Dec 2005 | -$740.21 M(+27.4%) | -$59.30 M(-56.9%) | -$740.21 M(-6.9%) |
| Sept 2005 | - | -$137.71 M(-38.5%) | -$795.32 M(+3.6%) |
| June 2005 | - | -$224.09 M(-29.8%) | -$767.92 M(+18.4%) |
| Mar 2005 | - | -$319.12 M(+178.9%) | -$648.77 M(+11.7%) |
| Dec 2004 | -$581.00 M(+59.0%) | -$114.41 M(+3.7%) | -$581.00 M(+24.5%) |
| Sept 2004 | - | -$110.30 M(+5.1%) | -$466.59 M(+31.0%) |
| June 2004 | - | -$104.94 M(-58.2%) | -$356.29 M(+41.8%) |
| Mar 2004 | - | -$251.34 M | -$251.34 M |
| Dec 2003 | -$365.44 M(+88.7%) | - | - |
| Dec 2002 | -$193.64 M(+70.7%) | - | - |
| Dec 2001 | -$113.45 M(-57.4%) | - | - |
| Dec 2000 | -$266.45 M(-861.5%) | - | - |
| Dec 1999 | $34.99 M(-113.6%) | - | - |
| Dec 1998 | -$257.97 M(-480.4%) | - | - |
| Dec 1997 | $67.81 M(-144.7%) | - | - |
| Dec 1996 | -$151.76 M(-54.0%) | - | - |
| Dec 1995 | -$330.04 M(-454.3%) | - | - |
| Dec 1994 | $93.15 M(-31.2%) | - | - |
| Dec 1993 | $135.48 M(-6.3%) | - | - |
| Dec 1992 | $144.55 M(-59.5%) | - | - |
| Dec 1991 | $356.99 M(+426.2%) | - | - |
| Dec 1990 | $67.84 M | - | - |
FAQ
- What is Novo Nordisk A/S annual cash flow from financing activities?
- What is the all time high annual CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual CFF year-on-year change?
- What is Novo Nordisk A/S quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly CFF year-on-year change?
- What is Novo Nordisk A/S TTM cash flow from financing activities?
- What is the all time high TTM CFF for Novo Nordisk A/S?
- What is Novo Nordisk A/S TTM CFF year-on-year change?
What is Novo Nordisk A/S annual cash flow from financing activities?
The current annual CFF of NVO is -$9.17 B
What is the all time high annual CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual cash flow from financing activities is $356.99 M
What is Novo Nordisk A/S annual CFF year-on-year change?
Over the past year, NVO annual cash flow from financing activities has changed by -$1.83 B (-24.88%)
What is Novo Nordisk A/S quarterly cash flow from financing activities?
The current quarterly CFF of NVO is -$2.74 B
What is the all time high quarterly CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly cash flow from financing activities is $2.44 B
What is Novo Nordisk A/S quarterly CFF year-on-year change?
Over the past year, NVO quarterly cash flow from financing activities has changed by +$151.01 M (+5.22%)
What is Novo Nordisk A/S TTM cash flow from financing activities?
The current TTM CFF of NVO is -$5.56 B
What is the all time high TTM CFF for Novo Nordisk A/S?
Novo Nordisk A/S all-time high TTM cash flow from financing activities is -$251.34 M
What is Novo Nordisk A/S TTM CFF year-on-year change?
Over the past year, NVO TTM cash flow from financing activities has changed by +$3.55 B (+38.94%)